• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    BioMarin Pharmaceutical (BMRN), What Is Behind The Fresh Attention?

    Simply Wall St·09/14/2026 16:17:51
    Listen to the news

    BioMarin Pharmaceutical (BMRN) is back in focus after new Phase 3 CANOPY-HCH-3 data for VOXZOGO in hypochondroplasia were published in NEJM Evidence and presented at the ESPE 2026 meeting, highlighting statistically significant growth benefits.

    BioMarin Pharmaceutical’s latest VOXZOGO data arrive at a time when the shares trade at US$65.68, with a 90-day share price return of 19.16% and a 1-year total shareholder return of 23.60%. However, the 3-year total shareholder return declined 25.87% and the 5-year total shareholder return fell 15.12%. This points to improving momentum in the short term as recent clinical results, the hypochondroplasia sNDA and a series of September healthcare conference appearances reset expectations around both growth prospects and perceived risk.

    Scan other rare disease and biotech opportunities showing similar clinical momentum with our curated list of 15 high quality undiscovered gems that pair growth potential with strong fundamentals.

    After a 19.16% rebound over 90 days and fresh VOXZOGO momentum, BioMarin Pharmaceutical still trades well below some implied value estimates. Has most of the rerating already played out, or is the bigger upside case still ahead?

    Most Popular Narrative: 28% Undervalued

    BioMarin Pharmaceutical’s most followed valuation view pegs fair value at $91.42 per share, comfortably above the recent $65.68 close. This view anchors that gap in a mix of royalty income, pipeline progress and margin assumptions rather than a simple sentiment swing.

    Strong year-over-year revenue growth driven by increasing global demand, new patient starts, and international expansion of key therapies like VOXZOGO and VIMIZIM aligns with demographic shifts and improved rare disease diagnosis, supporting continued top-line revenue growth.

    Accelerated pipeline advancement, including late-stage programs (BMN 333 for achondroplasia, BMN 401 for ENPP1 deficiency, and label expansions for PALYNZIQ), positions BioMarin to capitalize on growing patient pools through earlier and more accurate genetic identification, which should expand future addressable markets and boost revenue.

    See why 40 investors see BioMarin Pharmaceutical as 28% undervalued.

    Result: Fair Value of $91.42 (UNDERVALUED)

    Still, this BioMarin Pharmaceutical narrative can crack if rare disease pricing pressure bites harder than expected or if key programs face costly regulatory or trial setbacks.

    Find out about the key risks to this BioMarin Pharmaceutical narrative.

    Next Steps

    Mixed sentiment around BioMarin Pharmaceutical is clear, with both concern and optimism shaping the story right now. Move quickly, review the underlying data, and weigh up the 3 key rewards and 4 important warning signs.

    Looking for more investment ideas beyond BioMarin Pharmaceutical?

    If you only focus on BioMarin Pharmaceutical, you might overlook other compelling setups. Use the screeners below to quickly surface candidates that fit your style.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.